Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Int J Mol Sci. 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263.
Immunotherapy has changed the therapeutic scenario of metastatic renal cell carcinoma (mRCC), however the evaluation of disease response to immune-checkpoint inhibitors is still an open challenge. Response evaluation criteria in solid tumors (RECIST) 1.1 criteria are the cornerstone of response assessment to anti-neoplastic treatments, but the use of anti-programmed death receptor 1 (PD1) and other immunotherapeutic agents has shown atypical patterns of response such as pseudoprogression. Therefore, immune-modified criteria have been developed in order to more accurately categorize the disease response, even though their use in the everyday clinical practice is still limited. In this review we summarize the available evidence on this topic, with particular focus on the application of immune-modified criteria in the setting of mRCC.
免疫疗法改变了转移性肾细胞癌（mRCC）的治疗格局，然而，免疫检查点抑制剂治疗效果的评估仍然是一个尚未解决的挑战。实体瘤反应评估标准（RECIST）1.1 标准是抗肿瘤治疗反应评估的基石，但抗程序性死亡受体 1（PD1）和其他免疫治疗药物的使用显示出非典型的反应模式，如假性进展。因此，已经开发了免疫修正标准，以便更准确地对疾病反应进行分类，尽管它们在日常临床实践中的应用仍然有限。在这篇综述中，我们总结了这一主题的现有证据，特别关注免疫修正标准在 mRCC 中的应用。
